11-keto-β-Boswellic Acid (Synonyms: 11-oxo-β-Boswellic acid,KBA) |
| رقم الكتالوجGC10821 |
11-Keto-beta-boswellic acid (11-Keto-β؛ -boswellic acid) هو حمض ثلاثي التيربينيك خماسي الحلقات من راتينج الأوليوجوم المستخرج من لحاء شجرة Boswellia serrate المعروف شعبياً باسم اللبان الهندي. 11-Keto-beta-boswellic acid له نشاط مضاد للالتهابات يرجع في المقام الأول إلى تثبيط 5-lipoxygenase (5-LOX) وما يليه من leukotriene والعامل النووي-kappa B (NF-κ ؛ B) التنشيط وعامل نخر الورم جيل ألفا إنتاج.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 17019-92-0
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
IC50: 35.8 μM: inhibits MCF-7 (human breast adenocarcinoma) [1].
37.9 μM: blocks A2780 (cis-platin resistant ovarian cancer cells) [1].
11-keto-β-Boswellic Acid, known as KBA, is a naturally occurring pentacyclic triterpene isolated from the gum resin of the tree Boswellia serrata. KBA is non-redox, specific leukotriene synthesis inhibitors through the inhibition of 5-lipoxygenase (5-LOX) which has anti-arthritic and anti-inflammatory activities. 5-LOX catalyzes essential fatty acids substrates into leukotrienes and a variety of other biologically active products. KBA is a novel activator of nuclear factor erythroid-2-related factor 2 (Nrf2), which protects against cerebral ischemic injury.
In vitro: KBA, concentration dependently, decreased the formation of leukotriene B4 and the synthesis of all 5-LOX products from endogenous arachidonic acid in rat peritoneal neutrophils. In contrast, KBA exerted no remarkable effects on the 12-lipoxygenase and cyclooxygenase activities. [2].
In vivo: Adult male Sprague–Dawley rats were injected KAB intraperitoneally at a dose of 25 mg/kg for 48 hours. KAB remarkably decreased infarct volumes as well as apoptotic cells at 1 h, and then increased neurologic scores when applied 48 h. Moreover, posttreatment with KBA induced the decrease of malondialdehyde levels and the increase of protein Nrf2 and heme oxygenase-1 expression in brain tissues, indicating that the Nrf2/HO-1 pathway was involved in the neuroprotection of KBA against oxidative stress-induced ischemic injury [3].
References:
[1]. Csuk, R., Barthel-Niesen, A., Barthel, A., Schffer, R., & Al-Harrasi, A. 11-Keto-boswellic acid derived amides and monodesmosidic saponins induce apoptosis in breast and cervical cancers cells. European Journal of Medicinal Chemistry. 2015; 100: 98-105.
[2]. Safayhi, H., Mack, T. H. O. M. A. S., Sabieraj, J. O. A. C. H. I. M., Anazodo, M. I., Subramanian, L. R., & Ammon, H. P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. Journal of Pharmacology and Experimental Therapeutics. 1992; 261(3):1143-1146.
[3]. Ding, Y., Chen, M., Wang, M., Li, Y., & Wen, A. Posttreatment with 11-Keto-β-Boswellic Acid Ameliorates Cerebral Ischemia–Reperfusion Injury: Nrf2/HO-1 Pathway as a Potential Mechanism. Molecular Neurobiology. 2014; 52(3): 1430-1439.
| Cas No. | 17019-92-0 | SDF | |
| المرادفات | 11-oxo-β-Boswellic acid,KBA | ||
| Chemical Name | (3α,4β)-3-hydroxy-11-oxo-urs-12-en-23-oic acid | ||
| Canonical SMILES | O=C1C=C2[C@](CC[C@]3(C)C2[C@@H](C)[C@H](C)CC3)(C)[C@]4(C)CCC5[C@@](C)(C(O)=O)[C@H](O)CC[C@]5(C)C41 | ||
| Formula | C30H46O4 | M.Wt | 470.4 |
| الذوبان | ≤5mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1259 mL | 10.6293 mL | 21.2585 mL |
| 5 mM | 0.4252 mL | 2.1259 mL | 4.2517 mL |
| 10 mM | 0.2126 mL | 1.0629 mL | 2.1259 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *